17. SUBSEQUENT EVENTS

On July 23, 2026, the Board of Directors (the "Board") of the Company appointed Michael Severino, M.D. as the CEO of the Company as well as a Class I director, to serve until the Company’s 2028 annual meeting of stockholders, effective July 28, 2026 (the “CEO Effective Date”). Dr. Severino succeeded Douglas Ingram, who retired from his position as CEO and stepped down as a

member of the Board as of the CEO Effective Date. Dr. Severino was granted equity awards with an aggregate grant date fair value of approximately $35.0 million, consisting of (i) approximately $11.7 million of restricted stock units vesting in equal installments on an annual basis over four years and (ii) approximately $23.3 million of premium priced stock options vesting at 25% on the first anniversary of the date of grant, with monthly vesting in substantially equal installments thereafter over the next three years, generally subject to continued employment.